Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Jennifer L. Good Sells 5,263 Shares

Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Jennifer L. Good sold 5,263 shares of Trevi Therapeutics stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $6.58, for a total transaction of $34,630.54. Following the transaction, the chief executive officer now directly owns 213,313 shares in the company, valued at approximately $1,403,599.54. This trade represents a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Trevi Therapeutics Stock Up 3.3 %

TRVI stock opened at $6.61 on Wednesday. The stock’s 50 day moving average is $4.70 and its two-hundred day moving average is $3.81. Trevi Therapeutics, Inc. has a 52-week low of $2.30 and a 52-week high of $7.39. The company has a market capitalization of $639.07 million, a PE ratio of -15.02 and a beta of 0.90.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. As a group, sell-side analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Institutional Investors Weigh In On Trevi Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TRVI. Summit Investment Advisors Inc. grew its stake in Trevi Therapeutics by 84.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after purchasing an additional 2,894 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after buying an additional 6,764 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Trevi Therapeutics in the 4th quarter worth approximately $49,000. Squarepoint Ops LLC bought a new stake in shares of Trevi Therapeutics in the 4th quarter valued at approximately $58,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Trevi Therapeutics during the 3rd quarter valued at approximately $63,000. Institutional investors own 95.76% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on TRVI shares. Needham & Company LLC reduced their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, March 19th. B. Riley restated a “buy” rating and set a $20.00 price objective (up previously from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $9.00 to $29.00 in a report on Monday, March 10th. D. Boral Capital restated a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Finally, Oppenheimer increased their price objective on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Trevi Therapeutics currently has an average rating of “Buy” and a consensus price target of $17.56.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.